PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RCKT vs. BMRN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RCKT and BMRN is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

RCKT vs. BMRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rocket Pharmaceuticals, Inc. (RCKT) and BioMarin Pharmaceutical Inc. (BMRN). The values are adjusted to include any dividend payments, if applicable.

-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-57.04%
-40.47%
RCKT
BMRN

Key characteristics

Sharpe Ratio

RCKT:

-1.20

BMRN:

-1.09

Sortino Ratio

RCKT:

-2.16

BMRN:

-1.37

Omega Ratio

RCKT:

0.77

BMRN:

0.78

Calmar Ratio

RCKT:

-0.73

BMRN:

-0.58

Martin Ratio

RCKT:

-1.71

BMRN:

-1.83

Ulcer Index

RCKT:

36.30%

BMRN:

18.61%

Daily Std Dev

RCKT:

51.71%

BMRN:

31.36%

Max Drawdown

RCKT:

-94.90%

BMRN:

-90.58%

Current Drawdown

RCKT:

-85.40%

BMRN:

-58.74%

Fundamentals

Market Cap

RCKT:

$1.10B

BMRN:

$11.73B

EPS

RCKT:

-$2.73

BMRN:

$1.67

Total Revenue (TTM)

RCKT:

$0.00

BMRN:

$2.10B

Gross Profit (TTM)

RCKT:

-$4.59M

BMRN:

$1.63B

EBITDA (TTM)

RCKT:

-$190.02M

BMRN:

$455.03M

Returns By Period

In the year-to-date period, RCKT achieves a -17.98% return, which is significantly lower than BMRN's -6.39% return.


RCKT

YTD

-17.98%

1M

-12.18%

6M

-54.82%

1Y

-60.59%

5Y*

-13.09%

10Y*

N/A

BMRN

YTD

-6.39%

1M

-5.34%

6M

-26.83%

1Y

-33.30%

5Y*

-6.98%

10Y*

-4.38%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RCKT vs. BMRN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RCKT
The Risk-Adjusted Performance Rank of RCKT is 33
Overall Rank
The Sharpe Ratio Rank of RCKT is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of RCKT is 11
Sortino Ratio Rank
The Omega Ratio Rank of RCKT is 33
Omega Ratio Rank
The Calmar Ratio Rank of RCKT is 77
Calmar Ratio Rank
The Martin Ratio Rank of RCKT is 22
Martin Ratio Rank

BMRN
The Risk-Adjusted Performance Rank of BMRN is 55
Overall Rank
The Sharpe Ratio Rank of BMRN is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of BMRN is 66
Sortino Ratio Rank
The Omega Ratio Rank of BMRN is 44
Omega Ratio Rank
The Calmar Ratio Rank of BMRN is 1313
Calmar Ratio Rank
The Martin Ratio Rank of BMRN is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RCKT vs. BMRN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Rocket Pharmaceuticals, Inc. (RCKT) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RCKT, currently valued at -1.20, compared to the broader market-2.000.002.004.00-1.20-1.09
The chart of Sortino ratio for RCKT, currently valued at -2.16, compared to the broader market-4.00-2.000.002.004.00-2.16-1.37
The chart of Omega ratio for RCKT, currently valued at 0.77, compared to the broader market0.501.001.502.000.770.78
The chart of Calmar ratio for RCKT, currently valued at -0.73, compared to the broader market0.002.004.006.00-0.73-0.58
The chart of Martin ratio for RCKT, currently valued at -1.71, compared to the broader market-10.000.0010.0020.0030.00-1.71-1.83
RCKT
BMRN

The current RCKT Sharpe Ratio is -1.20, which is comparable to the BMRN Sharpe Ratio of -1.09. The chart below compares the historical Sharpe Ratios of RCKT and BMRN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50AugustSeptemberOctoberNovemberDecember2025
-1.20
-1.09
RCKT
BMRN

Dividends

RCKT vs. BMRN - Dividend Comparison

Neither RCKT nor BMRN has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RCKT vs. BMRN - Drawdown Comparison

The maximum RCKT drawdown since its inception was -94.90%, roughly equal to the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for RCKT and BMRN. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%AugustSeptemberOctoberNovemberDecember2025
-85.40%
-58.74%
RCKT
BMRN

Volatility

RCKT vs. BMRN - Volatility Comparison

Rocket Pharmaceuticals, Inc. (RCKT) has a higher volatility of 15.05% compared to BioMarin Pharmaceutical Inc. (BMRN) at 8.54%. This indicates that RCKT's price experiences larger fluctuations and is considered to be riskier than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%AugustSeptemberOctoberNovemberDecember2025
15.05%
8.54%
RCKT
BMRN

Financials

RCKT vs. BMRN - Financials Comparison

This section allows you to compare key financial metrics between Rocket Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab